Effects of a ceramide-containing water-in-oil ointment on skin barrier function and allergen penetration in an IL-31 treated 3D model of the disrupted skin barrier
Atopic dermatitis (AD) is a chronically relapsing, pruritic inflammation of the skin with dryness and disturbed skin barrier function. Recently, we established that IL-31 treatment of human 3D skin models resulted in a disrupted skin barrier phenotype resembling AD. In this model, we found that IL-31 interferes with the differentiation of keratinocytes and inhibits the expression of terminal differentiation markers. In the present study, we investigated the effects of a ceramide-containing water-in-oil skin care ointment on the physical skin barrier structure and function in disrupted skin barrier models, generated either by using primary normal human epidermal keratinocytes (NHEK) or HaCaT cells. We observed that the physical skin barrier of the models recovered after daily topical treatment with the ceramide-containing ointment. Topical application of the ointment prevented downregulation of filaggrin and disorganization of other differentiation markers, such as keratin 10 and 4-integrin, as demonstrated by immunohistological analysis. The expression of Ki67 was also upregulated in response to the ointment. Furthermore, functional studies revealed that local application of the ointment diminished the increased uptake of fluorescently labelled recombinant allergens of timothy grass (phl p1) in our model. In conclusion, our data revealed that topical application of a ceramide-containing skin care ointment reduced IL-31 induced impairments of the physical skin barrier and skin barrier function in an in vitro model of the disrupted skin barrier. This standardized model can be utilized in the future to monitor ex vivo effects of various topical therapies on skin morphology, physiology, and gene expression.
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Maruho Co Ltd, Drug Dev Res Labs, Kyoto R&D Ctr, 93 Chudoji Awata Cho,Shimogyo Ku, Kyoto 6008815, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Koda, AKira
Ishii, Yuko
论文数: 0引用数: 0
h-index: 0
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Ishii, Yuko
Kashiwagi, Ayu
论文数: 0引用数: 0
h-index: 0
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Kashiwagi, Ayu
Fujikawa, Mika
论文数: 0引用数: 0
h-index: 0
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Fujikawa, Mika
Kikuchi, Keisuke
论文数: 0引用数: 0
h-index: 0
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Kikuchi, Keisuke
Hashimoto, Ryota
论文数: 0引用数: 0
h-index: 0
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Hashimoto, Ryota
Ueda, Yuhki
论文数: 0引用数: 0
h-index: 0
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan
Ueda, Yuhki
Doi, Takaaki
论文数: 0引用数: 0
h-index: 0
机构:
Maruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, JapanMaruho Co Ltd, Drug Dev Labs, Drug Dev Res Labs, Kyoto R&D Ctr, Kyoto, Japan